Drug Database
TI

timolol (Ophtim / timolol, Thea)

✓ Approved

Takeda · ADRB1 · 小分子

什么是 timolol?

timolol 是一种小分子,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名Ophtim, timolol, Thea
公司Takeda
药物类别小分子
分子靶点ADRB1, ADRB2
给药途径Others
状态Approved

作用机制

分子靶点

timolol 作用于 2 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (B2AR, ADRBR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

timolol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedExpert opinion on drug safety2026-11-18

Ocular hyperemia with netarsudil/latanoprost fixed combination in glaucoma: an exploratory association analysis of tolerability outcomes by prior topical therapy and baseline ocular hyperemia.

Holló Gábor G

This post hoc analysis of MERCURY-3 evaluates factors associated with baseline ocular hyperemia and tolerability outcomes with netarsudil/latanoprost fixed combination (NET/LAT). MERCURY-3 was a prospective, randomized, double-masked, multicenter, Phase 3, European trial. Adults with open-angle glaucoma or ocular hypertension inadequately controlled on topical therapy were randomized to once-daily NET/LAT (n = 218) or bimatoprost/timolol fixed combination (BIM/TIM; n = 212) for 6 months. Patients were stratified by baseline ocular hyperemia status (none vs any grade) and associations with prior treatment, adverse events (AEs), and hyperemia evolution evaluated. In the NET/LAT arm, prior combination therapy was associated with a greater prevalence of baseline ocular hyperemia than prior monotherapy (distribution: p = 0.003). Patients with baseline hyperemia experienced higher rates of AEs (85% vs 63%), ocular treatment-related AEs (74% vs 39%), and conjunctival hyperemia (45% vs 26%) during treatment. Ocular hyperemia remained predominantly mild throughout follow-up, with a more stable severity trajectory linked to prior monotherapy compared with prior combination therapy. No comparable associations were observed with BIM/TIM. Prior treatment complexity and baseline ocular hyperemia status are associated with tolerability outcomes during NET/LAT therapy. These exploratory findings suggest that earlier step-up after monotherapy could be associated with more favorable tolerability. CT.gov identifier: NCT03284853.

PMID 43046532
阅读全文 →
PubMedInternational medical case reports journal2026-11-17

Management of Ahmed Glaucoma Valve Plate Exposure by Plate Removal and Tube Retention: A Case Report.

Alhemyari Mohammed S MS, Al-Hamdi Ibrahim Mohammed IM, Alhemyari Khalid K, Bamashmus Mahfouth A MA

Ahmed glaucoma valve (AGV) implantation is an established option for refractory glaucoma, including neovascular glaucoma (NVG). Exposure of glaucoma drainage device hardware is a serious complication because it increases the risk of infection and may require surgical repair or explantation. A 66-year-old man with diabetes, hypertension, and NVG secondary to diabetic retinopathy developed AGV plate exposure in the right eye two months after implantation. The exposed plate was removed while the tube was retained. The distal open end of the retained tube was positioned subconjunctivally approximately 8 mm posterior to the limbus beneath conjunctival/Tenon tissue. The tube was fixed to the sclera with 10-0 nylon, temporarily ligated with 7-0 Vicryl, and three fenestrations were created proximal to the ligature. Two weeks later, conjunctival wound dehiscence with tube exposure occurred and was repaired with an approximately 4 × 2 mm preserved scleral patch graft. At eight months after the final repair, the eye was quiet, the tube remained covered, and IOP was 14 mmHg while the patient was using dorzolamide-timolol. Tube function was not objectively confirmed. This case suggests that removal of an exposed Ahmed glaucoma valve (AGV) plate with retention of the tube may preserve a potential aqueous drainage pathway. However, subsequent conjunctival wound dehiscence and tube exposure required repair with a preserved scleral patch graft, highlighting the importance of adequate tube coverage, particularly in eyes with compromised conjunctiva. Following repair, tube coverage remained intact and intraocular pressure remained stable during eight months of follow-up, although the independent contribution of the retained tube to IOP control could not be confirmed. Longer follow-up and additional cases are needed to establish the efficacy and safety of this individualized approach.

PMID 43041822
阅读全文 →
PubMedCirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica2026-11-06

Topical timolol in the treatment of pediatric pyogenic granuloma: A 23-case series.

Sánchez Pulido L J LJ, Vega Mata N N, Enríquez Zarabozo E M EM, Granell Suárez C C et al.

Pyogenic granuloma (PG) is a common benign vascular lesion in pediatric patients, characterized by rapid growth and a tendency to bleed. Surgical excision allows immediate resolution and histological confirmation, with low recurrence when including the base of the lesion, although it may require anesthesia and leave a scar. Topical timolol has emerged as a conservative alternative in selected patients. To evaluate the efficacy and safety of topical timolol 0.5% in the treatment of PG in pediatric patients. Retrospective case series of 23 pediatric patients (4 months-13 years) diagnosed with PG and treated between 2018 and 2024 with a 0.5% timolol formulation applied topically over the lesion as an off-label use. Demographic and clinical variables, treatment duration, final response, need for surgery, recurrence, and documented adverse events were analyzed. Ten patients (43.5%) achieved complete or near-complete resolution of the lesion, 6 (26.1%) showed a partial response at the end of treatment or prior to surgery, 5 (21.7%) did not respond or exhibited progression, and 2 (8.7%) were still receiving treatment at data cutoff. Twelve patients completed treatment without surgery; at cutoff, 14 (60.9%) had not undergone surgery, including the 2 cases still under treatment. Nine patients (39.1%) required surgery. No recurrences were documented among patients with complete or near-complete resolution during available follow-up, and no adverse events attributable to treatment were recorded. Topical timolol 0.5% can be considered an initial conservative alternative in selected pediatric patients, especially when avoiding or deferring surgery or anesthesia is desired. Surgery remains a definitive option, offering immediate resolution and the possibility of histological confirmation. Prospective comparative studies are needed to define more precisely the role of timolol compared to surgical treatment.

PMID 42992436
阅读全文 →
PubMedIndian journal of pediatrics2026-11-05

Vision-Threatening Giant Hemifacial Infantile Hemangioma Successfully Treated with Oral Propranolol and Topical Timolol.

Sarkar Sumantra S, Bandyopadhyay Rakhi R, Raza Arsalan A

PMID 42986507
阅读全文 →
PubMedPediatric dermatology2026-11-04

Clinical Outcomes of Nasal Tip Infantile Hemangiomas: A Retrospective Cohort Study.

Belmesk Lina L, Coulombe Jerome J, Powell Julie J, Tehrany Yassaman Alipour YA et al.

Infantile hemangiomas (IH) are the most common vascular tumors in infancy. Nasal tip infantile hemangiomas (NTIH) are associated with high-risk disfigurement and long-term sequelae. Despite widespread use of propranolol, optimal management of NTIH remains incompletely defined. A retrospective cohort study included patients with NTIH evaluated between 2003 and 2019 at a pediatric referral center. Inclusion required confirmed diagnosis by two pediatric dermatologists, available clinical photographs, and ≥ 6 months of follow-up. Data collected included demographics, IH subtype, treatments, adverse events, and sequelae at 3 years old. Propranolol-treated patients were stratified by dose (≤ 2.5 vs. > 2.5 mg/kg/day). Fifty-eight patients met inclusion criteria. Propranolol was prescribed in 72.4% (n = 42), with a mean duration of 16.0 months. Adverse effects were predominantly mild (sleep disturbances, 20.7%). At 3 years of age, sequelae, particularly fibroadipose tissue, were significantly less frequent in propranolol-treated patients compared to those untreated (42.9% vs. 91.8%, p = 0.005; overall sequelae: 67.9% vs. 100%, p = 0.037). Sequelae rates did not differ between low- and high-dose propranolol groups. Combined propranolol and topical timolol was associated with increased telangiectatic sequelae, likely reflecting treatment selection bias. No association was found between IH subtype and sequelae. Systemic propranolol was associated with fewer long-term sequelae in NTIH, particularly fibroadipose tissue. A lower dose of 2 mg/kg/day appears sufficient in most cases. Topical timolol may provide limited additional benefit and should not delay propranolol initiation. These findings support early systemic propranolol as the standard of care in NTIH management.

PMID 42978517
阅读全文 →
PubMedArchives of medical research2026-10-27

Locus Coeruleus Stimulation Enhances Object Recognition Memory Persistence After Early-Life Stress Independent of Hippocampal Noradrenergic Signaling.

Neves Ben-Hur Souto das BSD, Lima Karine Ramires KR, Rosa Ana Carolina de Souza da ACSD, Gomes Gabriela Cristiane Mendes GCM et al.

Early-life stress, such as maternal deprivation (MD), is a stressor that can lead to cognitive deficits in adulthood. Among the neurochemical mechanisms involved in MD-induced pathophysiology are alterations in the dopaminergic and noradrenergic systems. We recently demonstrated that pharmacological stimulation of dopaminergic neurons in the ventral tegmental area (VTA) improves novel object recognition (NOR) memory in rats subjected to MD. Furthermore, projections from the locus coeruleus (LC) to the dorsal hippocampus (DH) are important for memory consolidation. From postnatal day (PND) 1-PND10, male and female rats were either subjected to MD or left undisturbed. In adulthood, the animals underwent stereotaxic surgery for bilateral cannulation of the DH and LC. Following recovery and habituation, the animals were trained in the NOR task and immediately received vehicle or timolol in the DH, and either vehicle or NMDA in the LC. NOR memory was assessed at 24 h, as well as 7 and 14 d after training, to evaluate memory consolidation and persistence, respectively. MD impaired NOR memory in male rats, but not in females. Pharmacological stimulation of the LC with NMDA promoted NOR memory persistence in both non-MD and MD males and females. In males, LC stimulation also reversed the MD-associated memory impairment. These effects were maintained despite hippocampal β-adrenergic receptor blockade with timolol. These findings suggest that LC-related pathways contribute to the processing of NOR memory persistence following early-life stress in a sex-dependent manner. This effect appears to be independent of hippocampal β-adrenergic signaling.

PMID 42945753
阅读全文 →

注册免费账户还可查看另外 4960 篇文献

免费注册查看全部文献 →

了解更多timolol